|Support type:||Scholarships in Brazil - Master|
|Effective date (Start):||November 01, 2016|
|Effective date (End):||February 28, 2018|
|Field of knowledge:||Health Sciences - Pharmacy - Medicines Analysis and Control|
|Principal Investigator:||Rosangela Gonçalves Peccinini|
|Grantee:||Evelin dos Santos Martins|
|Home Institution:||Faculdade de Ciências Farmacêuticas (FCFAR). Universidade Estadual Paulista (UNESP). Campus de Araraquara. Araraquara , SP, Brazil|
Efavirenz is a non-nucleoside reverse transcriptase inhibitor (NNRTI) commonly used on the treatment of Acquired Immunodeficiency Syndrome (AIDS) due its potent antiviral activity and clinical effectiveness when combined with two nucleoside reverse transcriptase inhibitors (NRTI) in the first line antiretroviral therapy (ART). Efavirenz is classified as class II in the Biopharmaceutics Classification System (BCS) and its oral bioavailability (Foral) in humans has a variable profile among individuals as a result of the influence of many factors, for instance, aqueous solubility and dissolution rate. The pharmaceutical technology offers many strategies which allows to optimize the dissolution rate and to increase bioavailability such as the use of functional excipients in inorganic nanoparticle, thereby reducing the dose and frequency of administrations and reducing the risk of side effects. This work focus on the evaluation and on the comparison of the pharmacokinetics of EFV transported through a inorganic nanoparticle, developed by Fontes and his team in the Federal University of Pernambuco, in relation to the free drug.